GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » Price-to-Operating-Cash-Flow

XTL Biopharmaceuticals (XTL Biopharmaceuticals) Price-to-Operating-Cash-Flow : (As of Apr. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-27), XTL Biopharmaceuticals's share price is $2.422. XTL Biopharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Hence, XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

XTLB's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

XTL Biopharmaceuticals's Cash Flow from Operations per share for the three months ended in Sep. 2023 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 4.80% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 19.90% per year.

During the past 13 years, XTL Biopharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 66.90% per year. The lowest was -107.20% per year. And the median was 17.70% per year.


XTL Biopharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Price-to-Operating-Cash-Flow Chart

XTL Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XTL Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow falls into.



XTL Biopharmaceuticals Price-to-Operating-Cash-Flow Calculation

XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=2.422/0
=

XTL Biopharmaceuticals's Share Price of today is $2.422.
XTL Biopharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

XTL Biopharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals (XTL Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Executives
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Samuel Rudman director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ben-zion Weiner director 3 HAYOGEV STREET, MOSHAV MAZOR L3 73160
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Michael Cho 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott Bradley 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
William Kessler officer: Director of Finance C/O XTL BIOPHARMACEUTICALS LTD., 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ron Bentsur officer: CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989